Intellia Therapeutics, Inc. (NTLA) vs Recursion Pharmaceuticals, Inc. (RXRX)
A side-by-side comparison of Intellia Therapeutics, Inc. and Recursion Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 2, 2026. Differences are shown without an overall score or investment verdict.
NTLA
Intellia Therapeutics, Inc.
$12.28HealthcareDelayed quote: Oct 2, 2026, 3:40 PM EDT
RXRX
Recursion Pharmaceuticals, Inc.
$4.08HealthcareDelayed quote: Oct 2, 2026, 3:40 PM EDT
Total return — NTLA vs RXRX
growth of $100 · dividends reinvested · last 5yNTLA -84.1% (-30.8%/yr)RXRX -77.4% (-25.7%/yr)RXRX compounded faster over this window
NTLA RXRX
NTLA vs RXRX: by the numbers
- •RXRX is the larger company ($2.14B vs $1.72B market cap).
- •Both run net losses; NTLA's is the smaller (-672.16% vs -945.92% net margin).
- •RXRX grew revenue faster over the past five years (45.50% vs 7.31% CAGR).
Metrics side by side
Valuation
| Metric | NTLA | RXRX |
|---|---|---|
| P/S ratio | 28.82 | 39.05 |
| P/B ratio | 2.36 | 2.34 |
Profitability
| Metric | NTLA | RXRX |
|---|---|---|
| Gross margin | 76.47% | -61.96% |
| Operating margin | -651.67% | -867.87% |
| Net margin | -672.16% | -945.92% |
| ROE | -54.96% | -56.71% |
| ROIC | -54.45% | -49.78% |
Growth (annualized)
| Metric | NTLA | RXRX |
|---|---|---|
| Revenue CAGR (5Y) | 7.31% | 45.50% |
| Total return CAGR (5Y) | -38.17% | -28.56% |
Frequently asked
- Which has grown faster, NTLA or RXRX?
- Over the past five years, RXRX grew revenue faster — NTLA at a 7.31% CAGR versus RXRX at 45.50%.
- How have NTLA and RXRX total returns compared?
- Over the past 5 years, NTLA delivered -38.17% and RXRX delivered -28.56% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Intellia Therapeutics ROERecursion Pharmaceuticals ROEIntellia Therapeutics operating marginRecursion Pharmaceuticals operating marginIntellia Therapeutics revenue growthRecursion Pharmaceuticals revenue growthIntellia Therapeutics free cash flowRecursion Pharmaceuticals free cash flow
Intellia Therapeutics & Recursion Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 2, 2026.